Forbes January 29, 2025
Could lives be endangered by cutting DEI?
Following President Trump’s executive order targeting diversity, equity and inclusion, the U.S. Food and Drug Administration has quietly taken down its draft guidance to drug and device makers to increase diverse populations for late-stage clinical trials It was due to be finalized by June 2025.
What’s the importance of diversity in clinical trials? To improve the results across a wider cross-section of patient groups historically excluded from these trials. The draft recognized that lack of diversity in test patients impacts the safety, efficacy, and dose requirements of certain drugs.
In June 2024, FDA Commissioner Robert M. Califf, MD, in a news release issued by the department stated:
“Participants in clinical trials should be...
Today's Sponsors
Today's Sponsor